Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. These viruses are engineered genetically for killing cancer. This chemokine is connected to the epidermal growth factor receptor (EGFR) antibody causing attachment to tumour cells.

Development 130

Development Research Antibody Engineer 130

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

OCTOBER 7, 2022

Surrozen and Boehringer Ingelheim have entered a partnership and licence agreement for researching and developing SZN-413 to treat retinal diseases. on meeting development, regulatory and commercial milestones, apart from sales-based royalty payments. A bi-specific antibody, SZN-413 acts on Fzd4-mediated Wnt signalling.

Development 147

Development Genetics Sales Antibody 147

Roots Analysis

FEBRUARY 27, 2024

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period.

Antibody 40

Antibody Marketing Drugs Contract Manufacturing 40

Drug Discovery World

JULY 6, 2023

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. Sema3A is upregulated in injured human kidneys and implicated in the development and progression of acute and chronic kidney diseases.

Antibody 52

Antibody Trials Genetics Protein 52

pharmaphorum

SEPTEMBER 14, 2020

Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics. US-based Merck, known as MSD outside North America, will globally develop and market Seattle’s investigational antibody-drug conjugate (ladiratuzumab vedotin).

Genetics 52

Genetics Development Drugs Protein 52

Pharmaceutical Technology

AUGUST 16, 2022

Q32 Bio has signed a partnership and option agreement with Horizon Therapeutics for developing ADX-914 to treat autoimmune ailments. According to the deal, Horizon will provide the funding to develop the therapy until the conclusion of its two Phase II clinical trials. Q32 will also receive tiered royalty payments on net sales.

Development 130

Development Clinical Trials Clinical Trials FDA Approval 130

Medical Xpress

FEBRUARY 7, 2023

Patients usually receive FVIII that comes from donor blood or is produced using genetic engineering. However, about one third of those treated for severe hemophilia A develop antibodies (inhibitors) against FVIII.

Antibody 40

Antibody Genetic Engineering Development Engineer 40

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 62

Development Research Drugs Antibody 62

Drug Discovery World

FEBRUARY 6, 2023

Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human immune system. MT: Can you provide me with an overview of what Infinimmune does currently and the potential it sees in the antibody-based therapeutics market?

Antibody 52

Antibody Immune Response Genome Genomics 52

Roots Analysis

OCTOBER 4, 2023

Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. I, recently, worked on a market research report, titled Bispecific Antibodies Market , 2023-2035. During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years.

Antibody 40

Antibody Genetics Drugs Development 40

BioPharma Reporter

SEPTEMBER 14, 2020

Merck and Seattle Genetics have announced two strategic oncology collaborations: one to develop Seattle Geneticsâ antibody-drug conjugate ladiratuzumab vedotin worldwide; and another to accelerate the global reach of Tukysa (tucatinib).

Genetics 66

Genetics Antibody Development Drugs 66

Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. All of our antibodies are highly validated using six pillars of validation, meaning that our antibodies do what we say they’ll do.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

MAY 3, 2024

SynOx Therapeutics has closed a $75m Series B financing round, which will be used to generate registrational Phase III clinical and CMC data for emactuzumab, the company’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).

Development 52

Development Genetic Disease Genetics Drugs 52

Scienmag

NOVEMBER 20, 2020

— A genetic modification in the ‘coat’ of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers. They say testing people for this and other viral mutations may help identify patients at risk for developing a fatal brain disease. HERSHEY, Pa.

Antibody 71

Antibody Genetics Medicine Development 71

The Pharma Data

APRIL 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

Antibody 40

Antibody Development Engineer Licensing 40

Drug Discovery World

MAY 6, 2024

Immune B cells could be used to develop cancer targeting immunotherapies, following new research by scientists at The Institute of Cancer Research, London, the University of Oxford and University of Cambridge. B cells are similar to T cell in that they work as part of the immune system to help fight infections as well as cancer.

Research 52

Research Immune Response Genetics Antibody 52

XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. They reported their findings last week in the journal Science.

Allergies 98

Allergies Antibody In-Vitro Development 98

Drug Discovery World

MARCH 24, 2023

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.

Vaccination 52

Vaccination Vaccine Development Genetics 52

XTalks

JULY 25, 2022

Oncologists also test for breast cancer subtypes, which are based on genetic characteristics, to determine the most appropriate treatment. Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). Vic-]Trastuzumab Duocarmazine Mechanism of Action.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

Roots Analysis

FEBRUARY 14, 2023

In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material.

Development 52

Development Manufacturing Drug Delivery Systems Contract Manufacturing 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. CHICAGO , Nov.

DNA 52

DNA Antibody Research Genome 52

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. We have been very impressed by their vision and the relevance of their platform.”.

Genome 105

Genome Genomics Medicine Development 105

XTalks

DECEMBER 28, 2023

BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene Therapy 246

Gene Therapy DNA Gene Genetics 246

Drug Discovery World

MARCH 25, 2024

“The potential for CAR T as a therapeutic option for autoimmune disease has captured the collective imagination of the scientific community,” said Zachary Roberts, Executive Vice President of Research & Development and Chief Medical Officer of Allogene.

Gene Editing 52

Gene Editing Drugs Genome Genomics 52

Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 3, 2023

It is in preclinical development to reverse immune evasion in STK11 mutated cancers. Tango Therapeutics president and CEO Dr Barbara Weber said: “FDA clearance of our IND application to initiate the TNG260 phase 1/2 trial is an important milestone in the development of this novel treatment for STK11-mutant cancers.

Clinical Trials 130

Clinical Trials Clinical Trials Genetics Antibody 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

Scienmag

SEPTEMBER 11, 2020

Credit: NIAID, 2020 A comprehensive analysis of antibody responses in coronavirus disease 2019 (COVID-19) patients could inform the development of an effective vaccine, according to a study published September 10 in the open-access journal PLOS Pathogens by Chao Wu and Rui Huang of Nanjing University Medical School, and colleagues.

Antibody 61

Antibody Vaccination Vaccine Development 61

Drug Discovery World

JANUARY 19, 2024

The top stories: Antibody cocktail effective against emerging Covid-19 variants Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants.

Drugs 52

Drugs Vaccination Vaccine Genetics 52

Drug Discovery World

APRIL 3, 2024

These figures demonstrate that the development of highly effective targeted therapeutics and immunotherapies is more important than ever, despite the astonishing rate of progress.

Research 52

Research Drugs Gene Therapy Genetics 52

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. executive vice president of research and development at Amgen. Reese , M.D.,

Antibody 52

Antibody Manufacturing Production Sales 52

Delveinsight

JANUARY 12, 2021

Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. It is an IgM antibody targeting Death Receptor 5 (DR5), and IGM is hoping to test Birinapant with IGM-8444 for the treatment of solid cancers later this year. R on macrophages.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

Drug Discovery World

NOVEMBER 9, 2023

DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: What kind of T-cell response can we expect from the MHC-targeting antibody fragment-based approach?

Antibody 62

Antibody Protein Development Engineer 62

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105